MedPath

Cardiovascular Performance and Exercise Response in Patients With Persistent or Permanent Atrial Fibrillation and Heart Failure Pre and Post Cardioversion or Pace and Ablate

Not yet recruiting
Conditions
Atrial Fibrillation (AF)
Pacemaker
Cardioversion
Heart Failure - NYHA II - IV
Ablation Therapy
Registration Number
NCT07205679
Lead Sponsor
Habib Khan
Brief Summary

Heart Failure (HF) and Atrial Fibrillation (AF) are two conditions that commonly occur together. Clinical guidelines consider a resting heart rate of 100-110 beats per minute (bpm) acceptable for patients with HF and AF while 72 bpm is considered the average in healthy populations. A higher resting heart rate indicates that the heart is working harder to meet bodily demands, and though it may be considered safe for patients with HF and AF to have a heart rate of 110 bpm, the investigators believe it is having a significant negative impact on patient quality of life and their ability to exercise. The current study will test exercise ability using a treadmill test before and after either a cardioversion, where the patient's heartbeat is reset using electric shocks, or a pace and ablate method, where the patient receives a pacemaker to regulate their heart rhythm and an ablation (intentional damaging) of the node that coordinates the beats within the heart. This will allow investigators to compare how the heart responds to exercise when the patient is on rate-control and anticoagulation medication therapy (before cardioversion or pace and ablate) and after the procedures. During exercise, the investigators will do a blood test that lets investigators know how efficiently the heart is working and record any symptoms experienced. The investigators will also collect information about the patient's quality of life. Using this information, the investigators hope to better understand whether the current standard of a resting heart rate of 100-110 bpm is ideal for patient quality of life.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
40
Inclusion Criteria
  1. Age ≥ 18
  2. Persistent or Permanent Atrial Fibrillation
  3. HF - NYHA class II-IVA despite guideline-direct medical therapy
  4. Rate controlled
  5. Able to perform stress test
  6. Scheduled for clinical P&A OR cardioversion
Exclusion Criteria
  1. Creatinine >180 μmol/L or eGFR <30 mL/min/1.73 m2
  2. Significant valvular heart disease: Moderate to severe tricuspid regurgitation, mitral regurgitation, mitral stenosis, aortic regurgitation, aortic stenosis
  3. Patients who have had a TAVI, valvular surgery, or CABG within 3 months of enrolment
  4. Right ventricular systolic pressure >50mmHg
  5. Existing pacemaker
  6. In sinus rhythm
  7. Predictable vasovagal syncope to pain and sight of blood

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Exercise duration1 month
Peak oxygen update1 month

Peak oxygen uptake achieved during a symptom-limited incremental exercise test to task failure.

B-type Natriuretic Peptide (BNP) Test1 month
Secondary Outcome Measures
NameTimeMethod
EuroQol (EQ-5D-5L)1 month

Participants indicate abilities with respect to five dimensions of health. Higher scores indicate greater impairment.

Rate of Perceived exertion change during exercise1 month
Change in maximal HR during exercise1 month
V̇O2peak change1 month
Change in lactate threshold1 month
Kansas City Cardiomyopathy Questionnaire1 month

Change in Kansas HF score from baseline. KCCQ is a 23-item self-administered questionnaire that measures the participant's perception of their health status, including their HF symptoms, impact on physical and social function and how their HF impacts the quality of life (QoL). KCCQ quantifies 7 domains: physical limitations (6 items), symptom stability (1 item), symptom frequency (4 items), symptom burden (3 items), self-efficacy (2 items), QoL (3 items) and social limitations (4 items). Scores were generated for each domain and scaled from 0 to 100, with 0 denoting the worst and 100 the best possible status.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.